A novel monoclonal antibody to cytokeratin 18 with reactivity toward lung squamous cell carcinomas and adenocarcinomas of various sites.
A novel monoclonal antibody to cytokeratin 18 with reactivity toward lung squamous cell carcinomas and adenocarcinomas of various sites.
复制标题
一种针对细胞角蛋白 18 的新型单克隆抗体，对不同部位的肺鳞状细胞癌和腺癌具有反应性。
DOI：
--
复制
发表时间：
1992
期刊：
影响因子：
--
通讯作者：
K. Lanks
中科院分区：
文献类型：
--
作者：
N. W. Chin;R. Zhang;D. C. Nostro;K. Lanks
细胞角蛋白(CKs)抗体在上皮性肿瘤的鉴别诊断中有着广泛的应用。链特异性抗CK试剂对癌症的进一步分型具有实用价值。作者用一种改进的免疫程序制备了一种新的抗CK-18单抗(ACK-156)，该方法包括连续注射人表皮角蛋白、环磷酰胺和从人肺癌细胞系中提取的浓缩细胞骨架提取物。这一方案有效地扩增了对表皮角蛋白中不存在的CK表位具有反应性的克隆。以总细胞裂解物和细胞骨架提取物为抗原的免疫印迹分析证实了抗体的单特异性。免疫过氧化物酶染色在包括肺在内的不同部位的腺癌中呈强阳性。肺鳞状细胞癌也呈强染色，而头颈部鳞状细胞癌呈灶性染色或完全不染色。相反，市面上几种抗CK-18的单抗并不能区分头颈部的肺鳞癌。对肿瘤裂解物的免疫印迹分析证实了组织染色结果，并显示测试的商用抗体除了识别ACK-156识别的CK 18肽外，至少还识别另一种低分子多肽。
Antibodies to cytokeratins (CKs) have found extensive application in the differential diagnosis of epithelial tumors. The chain-specific anti-CK reagents appear to be of practical value for further subtyping of carcinomas. The authors have produced a novel anti-CK 18 monoclonal antibody (ACK-156) using a modified immunization procedure that included sequential injections of human epidermal keratin, cyclophosphamide, and enriched cytoskeletal extracts from a human lung carcinoma cell line. This protocol effectively amplified clones with reactivity toward CK epitopes not present in epidermal keratin. Monospecificity of the antibody was confirmed by immunoblot analysis using both total cell lysates and cytoskeletal extracts as antigens. Immunoperoxidase staining of adenocarcinomas from a variety of sites, including lung, was strongly positive. Squamous cell carcinomas of lung were also strongly stained whereas squamous cell carcinomas of head and neck origin were stained focally or not at all. In contrast, several commercially available anti-CK 18 monoclonal antibodies did not distinguish squamous cell carcinomas of lung from those of head and neck origin. Immunoblot analysis of tumor lysates corroborated the tissue staining results and revealed that the commercially available antibodies that were tested recognize at least one other low molecular weight peptide in addition to the CK 18 peptide recognized by ACK-156.